Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Receivables - Other (2016 - 2021)

Historic Receivables - Other for Myriad Genetics (MYGN) over the last 12 years, with Q1 2021 value amounting to $2.4 million.

  • Myriad Genetics' Receivables - Other fell 400.0% to $2.4 million in Q1 2021 from the same period last year, while for Mar 2021 it was $2.4 million, marking a year-over-year decrease of 400.0%. This contributed to the annual value of $2.0 million for FY2020, which is N/A changed from last year.
  • Myriad Genetics' Receivables - Other amounted to $2.4 million in Q1 2021, which was down 400.0% from $2.0 million recorded in Q4 2020.
  • Myriad Genetics' 5-year Receivables - Other high stood at $6.9 million for Q3 2017, and its period low was $2.0 million during Q3 2020.
  • For the 5-year period, Myriad Genetics' Receivables - Other averaged around $4.1 million, with its median value being $4.3 million (2018).
  • Its Receivables - Other has fluctuated over the past 5 years, first soared by 7272.73% in 2017, then crashed by 5833.33% in 2020.
  • Quarter analysis of 5 years shows Myriad Genetics' Receivables - Other stood at $6.0 million in 2017, then dropped by 1.67% to $5.9 million in 2018, then tumbled by 40.68% to $3.5 million in 2019, then plummeted by 42.86% to $2.0 million in 2020, then rose by 20.0% to $2.4 million in 2021.
  • Its Receivables - Other was $2.4 million in Q1 2021, compared to $2.0 million in Q4 2020 and $2.0 million in Q3 2020.